产品名称
Fractogel EMD TMAE (M), strong anion exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)
ligand
(Trimethylammoniumethyl)
Quality Level
product line
Fractogel®
form
resin
parameter
240 cm/hr flow rate
8 bar max. pressure
matrix active group
methacrylate
mean particle size
40-90 μm
capacity
100 mg binding capacity (BSA/mg of resin)
transition temp
flash point 35 °C (calculated)
density
1.430 g/cm3 at 20 °C
bulk density
1000 kg/m3
application(s)
gene therapy
mAb
recombinant protein
separation technique
anion exchange
strong anion exchange
storage temp.
no temp limit
正在寻找类似产品? 访问 产品对比指南
Analysis Note
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1.0 bar
Particle size (d10): 37 - 45 µm
Particle size (d50): 48 - 60 µm
Particle size (d90): 63 - 77 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (bovine serum albumin): 80 - 120 mg/ml
Functional test (b:a): ≤ 0.25
Functional test: Separation of conalbumin and human serum albumin
Features and Benefits
- High protein loading conditions resulting in good selectivity and resolution with the tentacle technology
- Excellent binding to large viruses at increased loading
- Homogenous binding with high selectivity and purity
- Reduce operating costs and resin replacement with enduring durability - allowing for multiple cycles of column regeneration and sanitization
- Compatibility with 2.5 % (v/v) aqueous benzyl alcohol containing 150 mM NaCl storage solution
General description
Packaging
- 1.16881.0100: Fractogel® EMD TMAE (M) Resin 100ml
- 1.16881.0010: Fractogel® EMD TMAE (M) Resin 10ml
- 1.16881.0500: Fractogel® EMD TMAE (M) Resin 500ml
- 1.16881.0050: Fractogel® EMD TMAE (M) Resin 50ml
Legal Information
signalword
Warning
hcodes
Hazard Classifications
Flam. Liq. 3
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
95.0 °F
flash_point_c
35 °C
商品
Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.
A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.
Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.
A cost-model compares modalities like viral vectors and mRNA for production scale decision-making.
相关内容
This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持